A detailed investigation of molecular mechanisms revealed targeting of key cellular carcinogenic pathways, namely, MAPK/JNK/p38 (role of ROS), NF-κB, EGFR/JAK2/STAT3, P13K/Akt, mTOR/P70S6K, c-Raf/ERK, GSK3β, FOXO1, FOXO3a, and p53, that concurrently operate in HNC and contribute to cancer progression and treatment resistance. The gene discussed is TP53; the disease is cancer.